The EMA Grants Orphan Drug Designation to Neurenatis NEU001 for the Treatment of Hirschsprung Disease
News Source : Financial Post
News Summary
- Neurenati Therapeutics Inc. is a biotechnology company dedicated to developing transformative therapies for rare pediatric diseases.
- Its lead program focuses on Hirschsprung disease (HD), a life-threatening congenital gastrointestinal (GI) disorder caused by the absence of nerve cells in parts of the lower GI tract.
- Neurenati’s IND-enabling preclinical program for NEU-001 is currently underway, with plans to initiate a first-in-human clinical trial by the end of 2026.
MONTREAL Neurenati Therapeutics Inc., a biotechnology company dedicated to developing transformative therapies for rare pediatric diseases, is pleased to announce that the European Medicines Agency ( [+4823 chars]
Never miss a story from us, subscribe to our newsletter